Abstract: The method for preventing progression to Type II Diabetes includes determining whether a subject possesses a risk variant expression profile demonstrating dysregulation of the IL-33/ST2 axis, and providing an intervention to prevent progression to Type II Diabetes and/or to reverse prediabetes, including modifications of diet and exercise, administration of one or more pharmaceutical compounds, or a combination thereof. The method may be useful to reduce the risk of developing complications associated with Type II Diabetes or prediabetes, such as heart disease, stroke, or obesity. The pharmaceutical compound may be one or more pharmaceuticals capable of reducing circulating cholesterol, reducing blood glucose levels, reducing blood pressure, or a combination thereof.

Abstract: The method for preventing progression to Type II Diabetes includes determining whether a subject possesses a risk variant expression profile demonstrating dysregulation of the IL-33/ST2 axis, and providing an intervention to prevent progression to Type II Diabetes and/or to reverse prediabetes, including modifications of diet and exercise, administration of one or more pharmaceutical compounds, or a combination thereof. The method may be useful to reduce the risk of developing complications associated with Type II Diabetes or prediabetes, such as heart disease, stroke, or obesity. The pharmaceutical compound may be one or more pharmaceuticals capable of reducing circulating cholesterol, reducing blood glucose levels, reducing blood pressure, or a combination thereof.

Abstract: The synthesis of ursolic acid nanoparticles includes dissolving ursolic acid powder in methanol, boiling water for five minutes, and adding the methanol solution to the boiled water dropwise at a flow rate of 0.1-0.3 ml/min under ultrasonic conditions. After sonication for 20 minutes, the contents are stirred for about 15 minutes, and then dried. Particle size distribution studies and TEM micrographs confirm the resulting product comprises nanoparticles. In vitro testing confirms the ursolic acid nanoparticles exhibit greater anticancer activity than conventional-size particles, and that the nanoparticles exhibit antimicrobial effect against gram positive and gram negative bacteria, as well as fungi.

Abstract: The synthesis of ursolic acid nanoparticles includes dissolving ursolic acid powder in methanol, boiling water for five minutes, and adding the methanol solution to the boiled water dropwise at a flow rate of 0.1-0.3 ml/min under ultrasonic conditions. After sonication for 20 minutes, the contents are stirred for about 15 minutes, and then dried. Particle size distribution studies and TEM micrographs confirm the resulting product comprises nanoparticles. In vitro testing confirms the ursolic acid nanoparticles exhibit greater anticancer activity than conventional-size particles, and that the nanoparticles exhibit antimicrobial effect against gram positive and gram negative bacteria, as well as fungi.

Abstract: The synthesis of ursolic acid nanoparticles includes dissolving ursolic acid powder in methanol, boiling water for five minutes, and adding the methanol solution to the boiled water dropwise at a flow rate of 0.1-0.3 ml/min under ultrasonic conditions. After sonication for 20 minutes, the contents are stirred for about 15 minutes, and then dried. Particle size distribution studies and TEM micrographs confirm the resulting product comprises nanoparticles. In vitro testing confirms the ursolic acid nanoparticles exhibit greater anticancer activity than conventional-size particles, and that the nanoparticles exhibit antimicrobial effect against gram positive and gram negative bacteria, as well as fungi.

Abstract: A system, nontransitory computer readable medium, and method are provided for extracting data from unstructured medical text. Data points are identified in unstructured medical text, where the data points are determined using a dictionary database. A value associated with each of the data points is determined from the unstructured medical text. Each of the data points is mapped to its respective value for extraction from the unstructured medical text.

Abstract: The synthesis of ursolic acid nanoparticles includes dissolving ursolic acid powder in methanol, boiling water for five minutes, and adding the methanol solution to the boiled water dropwise at a flow rate of 0.1-0.3 ml/min under ultrasonic conditions. After sonication for 20 minutes, the contents are stirred for about 15 minutes, and then dried. Particle size distribution studies and TEM micrographs confirm the resulting product comprises nanoparticles. In vitro testing confirms the ursolic acid nanoparticles exhibit greater anticancer activity than conventional-size particles, and that the nanoparticles exhibit antimicrobial effect against gram positive and gram negative bacteria, as well as fungi.

Abstract: The synthesis of ursolic acid nanoparticles includes dissolving ursolic acid powder in methanol, boiling water for five minutes, and adding the methanol solution to the boiled water dropwise at a flow rate of 0.1-0.3 ml/min under ultrasonic conditions. After sonication for 20 minutes, the contents are stirred for about 15 minutes, and then dried. Particle size distribution studies and TEM micrographs confirm the resulting product comprises nanoparticles. In vitro testing confirms the ursolic acid nanoparticles exhibit greater anticancer activity than conventional-size particles, and that the nanoparticles exhibit antimicrobial effect against gram positive and gram negative bacteria, as well as fungi.

Abstract: The synthesis of ursolic acid nanoparticles includes dissolving ursolic acid powder in methanol, boiling water for five minutes, and adding the methanol solution to the boiled water dropwise at a flow rate of 0.1-0.3 ml/min under ultrasonic conditions. After sonication for 20 minutes, the contents are stirred for about 15 minutes, and then dried. Particle size distribution studies and TEM micrographs confirm the resulting product comprises nanoparticles. In vitro testing confirms the ursolic acid nanoparticles exhibit greater anticancer activity than conventional-size particles, and that the nanoparticles exhibit antimicrobial effect against gram positive and gram negative bacteria, as well as fungi.

Abstract: A photovoltaic cell includes a junction, formed from an n-type semiconductor material and a p-type semiconductor material, a trench, opening toward the light-incident side of the junction, for trapping reflected light, and two photon conversion layers. A first photon conversion layer, arranged at the light-incident side of the junction, converts photons from a higher energy to a lower energy suitable for absorption by the semiconductor material, and a second photon conversion layer, arranged at the opposite side of the junction, converts photons from a lower energy to a higher energy suitable for absorption by the semiconductor material.

Abstract: The synthesis of ursolic acid nanoparticles includes dissolving ursolic acid powder in methanol, boiling water for five minutes, and adding the methanol solution to the boiled water dropwise at a flow rate of 0.1-0.3 ml/min under ultrasonic conditions. After sonication for 20 minutes, the contents are stirred for about 15 minutes, and then dried. Particle size distribution studies and TEM micrographs confirm the resulting product comprises nanoparticles. In vitro testing confirms the ursolic acid nanoparticles exhibit greater anticancer activity than conventional-size particles, and that the nanoparticles exhibit antimicrobial effect against gram positive and gram negative bacteria, as well as fungi.

Abstract: A system for practitioner-patient network communicating real-time health data, location and prescription calendar scheduling is provided that enables health care practitioners to monitor patients in real-time by patient location. Prescriptions may be generated, amended, renewed, and authorized in real-time over network. Data transmitted over network may be packaged with a unique patient identity parsed into the data stream whereby unique security protocols ensure point-to-point delivery.

Abstract: A photovoltaic cell includes a junction, formed from an n-type semiconductor material and a p-type semiconductor material, a trench, opening toward the light-incident side of the junction, for trapping reflected light, and two photon conversion layers. A first photon conversion layer, arranged at the light-incident side of the junction, converts photons from a higher energy to a lower energy suitable for absorption by the semiconductor material, and a second photon conversion layer, arranged at the opposite side of the junction, converts photons from a lower energy to a higher energy suitable for absorption by the semiconductor material.

Abstract: A system, nontransitory computer readable medium, and method are provided for extracting data from unstructured medical text. Data points are identified in unstructured medical text, where the data points are determined using a dictionary database. A value associated with each of the data points is determined from the unstructured medical text. Each of the data points is mapped to its respective value for extraction from the unstructured medical text.

Abstract: A photovoltaic cell includes a junction, formed from an n-type semiconductor material and a p-type semiconductor material, a trench, opening toward the light-incident side of the junction, for trapping reflected light, and two photon conversion layers. A first photon conversion layer, arranged at the light-incident side of the junction, converts photons from a higher energy to a lower energy suitable for absorption by the semiconductor material, and a second photon conversion layer, arranged at the opposite side of the junction, converts photons from a lower energy to a higher energy suitable for absorption by the semiconductor material.

Abstract: The present invention relates to a pharmaceutical formulation comprising therapeutically effective amount of vildagliptin or pharmaceutically acceptable salt thereof and a diluent. Particularly, the ratio of vildagliptin to diluent is in the range of 0.04 to 0.24 (w/w).

Abstract: An automated medical test data report, tracking, and patient matching system devised to enable secure transmittal of medical test results data over network between a hosting computing apparatus and at least one receiving computing apparatus is provided. Triple tiered security is enabled by action of paired cryptographic keys, sequencing of data by generation of a randomized and securely-shared sequencing order, and fragmentation of data from a data stream into sortable data packets routable to separate and remotely connected partitions by appending a sort code into each data packet collectively prevent compromise of data in transmission over network.

Abstract: A practitioner network and appointment management system is presented that coordinates between end users and practitioners to enable networked appointment scheduling and management. The system includes an end user side and a practitioner side. End user side enables control of a scalable interactive map whereon practitioner data points are displayable by medical discipline. Practitioner first order data (including time to availability) is visually cued. Selection of a practitioner data point enables end user entry to a practitioner queue, which updates practitioner first order data across the network. Patient data is automatically transferrable to the practitioner queue by secure protocol. Practitioner side enables access of practitioner queue and selection of patients occupying designated slots therein to view associated patient data. Patient locations are displayable to practitioner for in-person visits. Practitioners can transfer patients into other practitioner queues.

Abstract: A method for coordinating medical treatments and in-care patient tracking system is set forth wherein a patient peripheral enables determination of patient location data, patient identification data, and treatment data, by sensed spatiotemporal relationships of the patient peripheral within a designated area. Proximity of the patient peripheral with a practitioner peripheral enables automated association of treatment data to a patient record alongside practitioner identification data. Treatment data generated, such as collected samples and other data, effects automatic assignment of the patient identity to relevant data and materials. Inventory is trackable, and doses administered are reportable automatically to the patient record.

Abstract: The present invention relates to a pharmaceutical formulation comprising therapeutically effective amount of vildagliptin or pharmaceutically acceptable salt thereof and a diluent. Particularly, the ratio of vildagliptin to diluent is in the range of 0.04 to 0.24 (w/w).